Inhibition of SGLT-2 using empagliflozin has been reported to ameliorate peritoneal fibrosis via suppressing TGF-β/Smad signaling (Shentu et al, 2021). This evidence concerns the gene SLC5A2 and Peritoneal Fibrosis.